DUBLIN–(BUSINESS WIRE)–The “Sustained Release Excipients Market Size, Share & Trends Analysis Report by Route Of Administration (Oral, Transdermal), by Technology (Transdermal, Implants), by Product (Gelatin, Sugars), and Segment Forecasts, 2022-2030” report has been added to ResearchAndMarkets.com’s offering.
The global sustained release excipients market size is expected to reach USD 2.4 billion by 2030, registering a CAGR of 8.22%
Rise in the number of patent expirations, need for pediatric & geriatric dosage forms, and added benefits provided by sustained release formulations are factors that are positively contributing to the market potential.
Sustained release formulations significantly reduce dosage frequency and improve patient compliance. These factors are further aiding industry growth. In comparison to conventional drugs, sustained drug release technologies provide a wide range of benefits.
Reduced dosage frequency, improved patient compliance, maintenance of the constant level of drug in blood plasma, lower instances of toxicity due to overdose, and higher cost-effectiveness, in the long run, are some of the major advantages of using sustained release drug delivery systems.
Regular consumption of oral conventional drugs generally results in undesired symptoms, such as gastrointestinal upset, cramps, nausea, and diarrhea. The use of sustained release drug formulations provides patients relief from these symptoms and helps maintain desired therapeutic drug levels in the body. Moreover, these have been increasing the adoption of sustained release formulations, enabling higher patient compliance and improved therapeutic effect.
Over the past few years, there has been a global rise in antibiotic resistance. Overuse and misuse of conventional drug formulations have been identified as the major cause of antibiotic resistance. In some instances, patients recover within a few days of drug administration and discontinue the recommended dose of drugs, culminating in resistance.
Such resistance leads to higher medical costs, longer hospital stays, and a rise in mortality rate. The rise in the incidence of infectious and chronic diseases has also resulted in antibiotic resistance, which has negatively impacted the conventional dosage forms market. Thus, alternative procedures to treat and manage these diseases are being implemented.
The use of controlled release formulations has been extensively accepted among physicians to prevent antibiotic resistance. Since these formulations generate preferred therapeutic drug levels in blood plasma and decrease the dosage frequency, they are an ideal choice of formulations among physicians, which increases their demand in the industry.
The impact of disruptions on pharmaceutical production and subsequently on excipient demand affected by lockdowns and transport and travel bans across several countries due to the COVID-19 pandemic will be comparatively short-term. However, the supply disruptions due to extended lockdowns in different countries may have a more substantial impact on the oral solid dosage form drug manufacturing.
This, in turn, will significantly impact the excipients’ demand growth globally. There is a wide scope for growth of the industry in Europe, which includes France, Spain, and Italy. This is due to the rising adoption of advanced drugs in these countries. Moreover, regulatory authorities, such as the European Medicines Agency (EMA) and Medicines & Healthcare Products Regulatory Agency (MHRA), are constantly working toward ensuring high safety standards and easy access to low-cost drugs in this region.
High disposable income, the presence of sophisticated healthcare infrastructure, and a rise in the number of product approvals are the factors expected to create growth opportunities in the Europe region.
Sustained release formulations are designed specifically in ways to reduce the dosage frequency. Thus, these formulations have high Active Pharmaceutical Ingredient (API) doses, which facilitate the maintenance of desired therapeutic levels. However, drug toxicity resulting from sustained release formulations is difficult to treat due to excess API.
Drug retrieval in these cases becomes difficult as drugs are designed to deliver predetermined amounts at frequent time intervals. These are very rarely seen in sustained release formulations, which may hinder industry growth to a certain extent.
Sustained Release Excipients Market Report Highlights
- The polymers product segment accounted for the largest share in 2021. Varied usage of polymers in sustained release formulations is anticipated to fuel industry growth
- Conventional use of the oral route of delivery has contributed to the segment’s growth. Convenience, in terms of storage, premeasured doses, portability, and noninvasive nature of this route are some of the major factors accelerating its adoption
- The rising adoption of transdermal patches has contributed to the growth of the segment
- Targeted drug delivery constituted the largest revenue share in 2021, as a large number of industry players have strong product portfolios. Implantable sustained release drug delivery systems have improved efficiency, lower adverse effects, and higher convenience, which impels segment growth
- Europe dominated the global industry in 2021 due to the high investments in R&D and availability of highly sophisticated technologies in the region
- Asia Pacific will register the fastest CAGR during the forecast period due to the growing pharmaceutical industry in emerging countries, such as India and China
Global Sustained Release Excipients Market Variables, Trends, & Scope
Market Driver Analysis
- Increased Benefits Over Conventional Dosage Forms
- Increased Acceptance Due To Nature Of Dosage Forms
- Necessity Of Pediatric And Geriatric Sustained Release Dosage Forms
- Antibiotic Resistance
Market Restraint Analysis
- Drug Toxicity Due To Dose Dumping
- Need For High Dose Of API
Market Challenge Analysis
- Patient Education And Counselling
- Higher Cost Of Sustained Release Systems In Comparison To Conventional Pharmaceutical Formulations
Key Opportunities
- Minimization Of Hepatic First Pass Elimination
- Development Cost-Efficient Dosage Forms
Sustained Release Excipients Market – PESTLE analysis
Industry Analysis – Porter’s
Major Deals and Strategic Alliances Analysis
- Joint Ventures
- Mergers And Acquisitions
- Licensing And Partnership
- Technology Collaborations
- Strategic Divestments
Covid-19 Impact Analysis
Competitive Landscape
- Teva Pharmaceutical Industries Ltd.
- Mylan N.V.
- Valeant Pharmaceuticals International, Inc.
- Pfizer, Inc.
- Sun Pharmaceutical Industries Ltd.
- Novartis AG
- Astrazeneca
- GlaxoSmithKline plc
- Allergan plc
- Janssen Pharmaceuticals, Inc.
- Mayne Pharma Group Limited
- Croda International plc
- Merck Kgaa
- Basf
- Ashland Global
- International Flavors & Fragrances, Inc.
- Evonik Industries
- Gattefosse
For more information about this report visit https://www.researchandmarkets.com/r/ib1544
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900